Below are our currently enrolling studies for patients with hypoparathyroidism.
Sponsor: Ascendis Pharma Bone Diseases A/S
Protocol Number: ASND0052
This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: MBX Biosciences
Protocol Number: MBX-2H1005
The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).
Detailed Information:
To learn more or see if you qualify: Click Here